van Diemen H A, Polman C H, van Dongen M M, Nauta J J, Strijers R L, van Loenen A C, Bertelsmann F W, Koetsier J C. 4-Aminopyridine induces functional improvement in multiple sclerosis patients: a neurophysiological study. J Neurol Sci 1993; 116: 220–226.

Yamaguchi S and Rogawski M A (1992): Effects of anticonvulsant drugs on 4-aminopyridine-induced seizures in mice. Epilepsy Res. 11:9–16.

Patents:

Effland R C, Klein J T, Davis K L Olsen G E; U.S. Pat. No. 4,970,218 entitled "N-(Pyridinyl)-1H-indol-1-amines".

Hansebout R R and Blight A R; U.S. Pat. No. 5,545,648 entitled "Use of 4-aminopyrdidine in the reduction of chronic pain and spasticity in a spinal cord injured patient".

Hansebout R R and Blight A R; WO 94/14439 entitled "The use of 4-aminopyridine in the treatment of a neurological condition".

Huger, F. P., Kongsamut, S., C. P. Smith & L. Tang. U.S. Pat. No. 5,776,955 entitled "Use of unsubstituted and substituted N-(pyrrol-1-yl) pyridinamines as anticonvulsant agents".

Kongsamut, S., C. P. Smith & A. T. Woods; U.S. Pat. No. 5,356,910 entitled "Use of N-(Pyridinyl)-1H-indol-1-amines for the Treatment of Obsessive Compulsive Disorder".

Kongsamut, S., C. P. Smith & A. T. Woods; U.S. Pat. No. 5,356,910 entitled "Use of N-(Pyridinyl)-1H-indol-1-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders".

Masterson J G and Myers M; U.S. Pat. No. 5,370,879 entitled "Formulations and their use in the treatment of neurological diseases".

Masterson J G and Myers M; U.S. Pat. No. 5,580,580 entitled "Formulations and their use in the treatment of neurological diseases".

Masterson J G and Myers M; U.S. Pat. No. 5,540,938 entitled "Formulations and their use in the treatment of neurological diseases".

Wurtman R J and Buyukysal R; WO 89/09600 entitled "Method and composition for treating neurological disorders".

The invention claimed is:

1. A method of treating Over Active Bladder said method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I



I

wherein

m is 0, 1 or 2;

n is 0, 1 or 2;

p is 0 or 1;

each R is independently hydrogen, halogen, trifluoromethyl, C_1–C_6alkyl, C_1–C_6alkoxy, benzyloxy, hydroxy, nitro or amino;

each R_1 is independently hydrogen, C_1–C_6alkyl, C_1–C_6alkenyl,

C_1–C_6alkanoyl, halogen, cyano, —C(O)C_1–C_6alkyl, —C_1–C_6alkyleneCN, —C_1–C_6alkyleneNR'R" wherein R' and R" are each independently hydrogen or C_1–C_6alkyl,

—C_1–C_6alkyleneOC(O)C_1–C_6alkyl, or —CH(OH)R_4 wherein R_4 is hydrogen or C_1–C_6alkyl;

R_2 is hydrogen, C_1–C_6alkyl optionally substituted with halogen, hydroxy or benzyloxy, C_1–C_6alkenyl, C_1–C_6alkynyl,

—CO_2C_1–C_6alkyl, or —R_5—NR' R" wherein R_5 is C_1–C_6alkylene, C_1–C_6alkenylene or C_1–C_6alkynylene and R' and R" are each independently hydrogen, C_1–C_6alkyl or alternatively the group —NR'R" as a whole is 1-pyrrolidinyl; and

R_3 is hydrogen, nitro, amino, halogen, C_1–C_6alkoxy, hydroxy or C_1–C_6alkyl

or a pharmaceutically acceptable salt thereof.

2. The method of claim **1** wherein the compound has the following formula:



* * * * *